WJOG6510GTR: Study of genetic biomarkers to predict efficacy in patients with wild-type KRAS metastatic colorectal cancer receiving Panitumumab + Irinotecan or Cetuximab + Irinotecan

Trial Profile

WJOG6510GTR: Study of genetic biomarkers to predict efficacy in patients with wild-type KRAS metastatic colorectal cancer receiving Panitumumab + Irinotecan or Cetuximab + Irinotecan

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 May 2015

At a glance

  • Drugs Cetuximab (Primary) ; Panitumumab (Primary) ; Irinotecan
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 28 May 2015 Status changed from recruiting to active, no longer recruiting University Hospital Medical Information Network - Japan.
    • 15 Jan 2014 Status changed from not yet recruiting to recruiting as per University Hospital Medical Information Network - Japan record.
    • 31 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top